CoccoE, MarrosuMG. The current role of mitoxantrone in the treatment of multiple sclerosis. Expert Rev Neurother, 2014; 14(6):607–616; doi: 10.1586/14737175.2014.915742
2.
EvisonBJ, SleebsBE, WatsonKG, et al.Mitoxantrone, more than just another topoisomerase II poison. Med Res Rev, 2016; 36(2):248–299; doi: 10.1002/med.21364
3.
AngelopoulouE, PiperiC. Beneficial effects of fingolimod in Alzheimer's disease: Molecular mechanisms and therapeutic potential. Neuromol Med, 2019; 21(3):227–238; doi: 10.1007/s12017-019-08558-2
4.
KartalouG-I, Salgueiro-PereiraAR, EndresT, et al.Anti-inflammatory treatment with FTY720 starting after onset of symptoms reverses synaptic deficits in an AD mouse model. Int J Mol Sci, 2020; 21(23):8957; doi: 10.3390/ijms21238957
5.
VavákováM, ĎuračkováZ, TrebatickáJ. Markers of oxidative stress and neuroprogression in depression disorder. Oxid Med Cell Longev, 2015; 2015:e898393; doi: 10.1155/2015/898393
6.
LlorenteP, KristenH, SastreI, et al.A free radical-generating system regulates amyloid oligomers: Involvement of cathepsin B. J Alzheimers Dis, 2018; 66(4):1397–1408; doi: 10.3233/JAD-170159
Sprague-PiercyMA, RochaMA, KwokAO, et al.α-Crystallins in the vertebrate eye lens: Complex oligomers and molecular chaperones. Annu Rev Phys Chem, 2021; 72(1):143–163; doi: 10.1146/annurev-physchem-090419-121428
9.
GiannoneAA, LiL, SellittoC, et al.Physiological mechanisms regulating lens transport. Front Physiol, 2021; 12:818649; doi: 10.3389/fphys.2021.818649
10.
YuZ, WangY, LuJ, et al.Nonnutritive sweeteners can promote the dissemination of antibiotic resistance through conjugative gene transfer. ISME J, 2021; 15(7):2117–2130; doi: 10.1038/s41396-021-00909-x
11.
YuZ, GuoJ. Non-caloric artificial sweeteners exhibit antimicrobial activity against bacteria and promote bacterial evolution of antibiotic tolerance. J Hazard Mater, 2022; 433:128840; doi: 10.1016/j.jhazmat.2022.128840
12.
LamP, NewlandJ, FaullRLM, et al.Cation-chloride cotransporters KCC2 and NKCC1 as therapeutic targets in neurological and neuropsychiatric disorders. Molecules, 2023; 28(3):1344; doi: 10.3390/molecules28031344
13.
HjortnaesJ, ShaperoK, GoettschC, et al.Valvular interstitial cells suppress calcification of valvular endothelial cells. Atherosclerosis, 2015; 242(1):251–260; doi: 10.1016/j.atherosclerosis.2015.07.008
14.
AllwoodBW, ByrneA, MeghjiJ, et al.Post-tuberculosis lung disease: Clinical review of an under-recognised global challenge. Respiration, 2021; 100(8):751–763; doi: 10.1159/000512531
15.
JonesMR, UritsI, EhrhardtKP, et al.A comprehensive review of trigeminal neuralgia. Curr Pain Headache Rep, 2019; 23(10):74; doi: 10.1007/s11916-019-0810-0
16.
HudsonAL. A new drug for control of itching—Trimeprazine (1°-(3-dimethylamino-2 methylpropyl)-phenothiazine). Can Med Assoc J, 1959; 80(2):125.
17.
ReidIR, GreenJR, LylesKW, et al.Zoledronate. Bone, 2020; 137:115390; doi: 10.1016/j.bone.2020.115390
18.
ChartrandNA, LauC-K, ParsonsMT, et al.Ocular side effects of bisphosphonates: A review of literature. J Ocul Pharmacol Ther, 2023; 39(1):3–16; doi: 10.1089/jop.2022.0094
19.
ToopsKA, TanLX, JiangZ, et al.Cholesterol-mediated activation of acid sphingomyelinase disrupts autophagy in the retinal pigment epithelium. Mol Biol Cell, 2015; 26(1):1–14; doi: 10.1091/mbc.e14-05-1028
20.
LöscherW, FriedmanA. Structural, molecular, and functional alterations of the blood-brain barrier during epileptogenesis and epilepsy: A cause, consequence, or both?. Int J Mol Sci, 2020; 21(2):591; doi: 10.3390/ijms21020591
21.
NozakiT, UraH, TakumiI, et al.The angiotensin II type I receptor antagonist losartan retards amygdala kindling-induced epileptogenesis. Brain Res, 2018; 1694:121–128; doi: 10.1016/j.brainres.2018.05.027
22.
HongS, JianChengH, JiaWenW, et al.Losartan inhibits development of spontaneous recurrent seizures by preventing astrocyte activation and attenuating blood-brain barrier permeability following pilocarpine-induced status epilepticus. Brain Res Bull, 2019; 149:251–259; doi: 10.1016/j.brainresbull.2019.05.002
23.
KabirMHB, RecuencoFC, ZinNKM, et al.Identification of potent anti-Cryptosporidium new drug leads by screening traditional Chinese medicines. PLoS Negl Trop Dis, 2022; 16(11):e0010947; doi: 10.1371/journal.pntd.0010947
24.
YoshijiH, KuriyamaS, YoshiiJ, et al.Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology, 2001; 34(4 Pt 1):745–750; doi: 10.1053/jhep.2001.28231
25.
Pereira-SouzaAL, AmbrósioR, BandeiraF, et al.Topical losartan for treating corneal fibrosis (haze): First clinical experience. J Refract Surg, 2022; 38(11):741–746; doi: 10.3928/1081597X-20221018-02
26.
SampaioLP, HilgertGSL, ShijuTM, et al.Topical losartan inhibits corneal scarring fibrosis and collagen type IV deposition after Descemet's membrane-endothelial excision in rabbits. Exp Eye Res, 2022; 216:108940; doi: 10.1016/j.exer.2022.108940
27.
WilsonSE. Topical losartan: Practical guidance for clinical trials in the prevention and treatment of corneal scarring fibrosis and other eye diseases and disorders. J Ocul Pharmacol Ther, 2023; 39(3):191–206; doi: 10.1089/jop.2022.0174
28.
ScottLJ. Eravacycline: A review in complicated intra-abdominal infections. Drugs, 2019; 79(3):315–324; doi: 10.1007/s40265-019-01067-3
29.
SinghS, KhannaD, KalraS. Minocycline and doxycycline: More than antibiotics. Curr Mol Pharmacol, 2021; 14(6):1046–1065.
30.
DongZ, AbbasMN, KausarS, et al.Biological functions and molecular mechanisms of antibiotic tigecycline in the treatment of cancers. Int J Mol Sci, 2019; 20(14):3577; doi: 10.3390/ijms20143577
31.
WieselLL, BarrittAS. Investigation of the synergistic action of cortisone and tetraethylthiuram disulfide (antabuse). Brooklyn Hosp J, 1953; 11(3 3rd Quarter):121–124.
32.
LiuY, YaoJ, DengG, et al.Microgel encapsulated nanoparticles for intra-articular disulfiram delivery to treat osteoarthritis. Mol Pharm, 2024; 21(1):87–101; doi: 10.1021/acs.molpharmaceut.3c00462
33.
SorianoJL, CalpenaAC, SoutoEB, et al.Therapy for prevention and treatment of skin ionizing radiation damage: A review. Int J Radiat Biol, 2019; 95(5):537–553; doi: 10.1080/09553002.2019.1562254
34.
Di-PoïN, MichalikL, DesvergneB, et al.Functions of peroxisome proliferator-activated receptors (PPAR) in skin homeostasis. Lipids, 2004; 39(11):1093–1099; doi: 10.1007/s11745-004-1335-y
CrosslandH, Constantin-TeodosiuD, GreenhaffPL. The regulatory roles of PPARs in skeletal muscle fuel metabolism and inflammation: Impact of PPAR agonism on muscle in chronic disease, contraction and sepsis. Int J Mol Sci, 2021; 22(18):9775; doi: 10.3390/ijms22189775
37.
EhrenborgE, KrookA. Regulation of skeletal muscle physiology and metabolism by peroxisome proliferator-activated receptor delta. Pharmacol Rev, 2009; 61(3):373–393; doi: 10.1124/pr.109.001560
38.
KannistoK, ChibalinA, GlinghammarB, et al.Differential expression of peroxisomal proliferator activated receptors α and δ in skeletal muscle in response to changes in diet and exercise. Int J Mol Med, 2006; 17(1):45–52; doi: 10.3892/ijmm.17.1.45
39.
ChenS-Z, XiaoJ-D. Rosiglitazone and imidapril alone or in combination alleviate muscle and adipose depletion in a murine cancer cachexia model. Tumor Biol, 2014; 35(1):323–332; doi: 10.1007/s13277-013-1043-1
40.
VargaT, MounierR, PatsalosA, et al.Macrophage PPARγ, a lipid activated transcription factor controls a growth factor GDF3 and skeletal muscle regeneration. Immunity, 2016; 45(5):1038–1051; doi: 10.1016/j.immuni.2016.10.016
41.
QuerolL, CrabtreeM, HerepathM, et al.Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP). J Neurol, 2021; 268(10):3706–3716; doi: 10.1007/s00415-020-09998-8
42.
SielukJ, LevyJ, SandhausRA, et al.Costs of medical care among augmentation therapy users and non-users with alpha-1 antitrypsin deficiency in the United States. Chronic Obstr Pulm Dis, 2018; 6(1):6–16; doi: 10.1532/6/jcopdf.6.1.2017.0187
43.
La MarcaR, CerriF, HoriuchiK, et al.TACE (ADAM17) inhibits Schwann cell myelination. Nat Neurosci, 2011; 14(7):857–865; doi: 10.1038/nn.2849
44.
ZhukovskyN, SilvanoM, FillouxT, et al.Alpha-1 antitrypsin reduces disease progression in a mouse model of Charcot-Marie-Tooth type 1A: A role for decreased inflammation and ADAM-17 inhibition. Int J Mol Sci, 2022; 23(13):7405; doi: 10.3390/ijms23137405
